

# Amendment Tool

v1.6 06 December 2021

For office use

QC: No

## Section 1: Project information

Short project title*:	The RECOVERY Trial			
IRAS project ID* (or REC reference if no IRAS project ID is available):	281712			
Sponsor amendment reference number*:	Substantial Amendment 33			
Sponsor amendment date* (enter as DD/MM/YY):	13 September 2023			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	1) Addition of a corticosteroid comparison for community-acquired pneumonia caused by pathogens other than SARS-CoV-2 and influenza 2) Update of RSI to current versions of the SmPC 3) Inclusion of sites in the EU 4) Minor change to baseline data collected			
Project type (select):	<b>Specific study</b>			
	Research tissue bank			
	Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<b>Yes</b>		No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	<b>NHS/HSC REC</b>			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a <b>modified amendment</b> (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes		<b>No</b>	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	<b>Yes</b>	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	<b>Yes</b>		No	
EudraCT number*:	2020-001113-21			
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the CTIMP combined review service (formerly known as the Combined Ways of Working (CWOW) pilot)?:	Yes		<b>No</b>	
Did the study receive Pharmacy Assurance?:	<b>Yes</b>		No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes		<b>No</b>	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	<b>Yes</b>		No	
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve children OR does the amendment introduce this?:	<b>Yes</b>		No	
Did the study involve NHS/HSC organisations prior to this amendment?:	<b>Yes</b>		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		<b>No</b>	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	<b>Yes</b>	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>
Which nations will have participating NHS/HSC organisations after this amendment?	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>

## Section 2: Summary of change(s)

What do you want to update?:	<b>Project information</b>
	New site/PI only

**Please note:** Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Inclusion/exclusion criteria - Significant change (e.g. to age range) likely to affect safety or scientific value of study			
Further information (free text - note that this field will adapt to the amount of text entered):	<p>1) Inclusion of participants with community-acquired pneumonia caused by pathogens other than SARS-CoV-2 and influenza. Patients admitted to hospital with pneumonia caused by SARS-CoV-2 and influenza are currently being recruited in RECOVERY, and this amendment would allow the inclusion of patients with the same clinical syndrome, but who do not have suspected or confirmed SARS-CoV-2 or influenza infection. Other inclusion and exclusion criteria are unchanged. Participants with CAP caused by pathogens other than SARS-COV-2 and influenza would be randomised between corticosteroids and usual care. The IMP and dosage are the same as for the current corticosteroid comparison for patients with pneumonia caused by influenza (dexamethasone 6mg daily, replaced with an equivalent dose of prednisolone or hydrocortisone for pregnant or breastfeeding women). A full justification is provided in the Justification for Protocol V27 document.</p> <p>2) Update of corticosteroid contraindications - patients on potent CYP3A4 inhibitors will only be excluded from the high dose dexamethasone comparison (not low dose dexamethasone comparisons). This is correcting an oversight when this contraindication was introduced in substantial amendment 25, as described in the Justification for Protocol V27 document).</p>			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 2				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	IB, SmPC - Non-substantial changes (e.g. that do not affect risk/benefit assessment)			
Further information (free text - note that this field will adapt to the amount of text entered):	Update of RSI for current study treatments. The SmPCs for oseltamivir, dexamethasone, prednisolone and hydrocortisone are updated to the current versions from 2021-2023. There are no substantial changes to the RSI in section 4.8, but as we are submitting an application to open the trial in the EU we would like to update these to the current versions. The oseltamivir SmPC has also been changed to the 75mg dose (from 45mg) as this is the dose used in RECOVERY.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 3				
Area of change (select)*:	Study Management			
Specific change (select - only available when area of change is selected first)*:	Non-UK countries - Inclusion or withdrawal of an EU Member State or third country			
Further information (free text - note that this field will adapt to the amount of text entered):	We are planning to open the trial at sites in France, Italy and the Netherlands.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes

Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All	Some
		Remove all changes below

Change 4				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other significant change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Addition of CAP comparison to adult information sheet and consent form.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All	Some		
				Remove all changes below

Change 5				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Protocol - Non-substantial changes (e.g. not affecting safety or the scientific value of the trial)			
Further information (free text - note that this field will adapt to the amount of text entered):	Minor changes to baseline data collection to inform characterisation of patients more appropriately (and to comply with data protection requirements in EU countries).			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All	Some		
				Add another change

### Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate	
<ul style="list-style-type: none"> <li>I confirm that the Sponsor takes responsibility for the completed amendment tool</li> <li>I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf</li> </ul>	
Applicant identification:	<b>Sponsor</b> Legal representative of the sponsor Person or organisation authorised by the sponsor
Organisation:	University of oxford
Name [first name and surname]*:	Heather House
Address:	RGEA, Boundary Brook House, Churchill Drive, Headington, Oxford, OX3 7GB
Telephone number:	
Fax number:	
Purchase Order (PO) number for MHRA invoicing:	H62020852
Email address*:	rgea.amend@admin.ox.ac.uk

Lock for submission
<b>Please note:</b> This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

#### Section 4: Review bodies for the amendment

**Please note:** This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies														Category:				
	UK wide:					England and Wales:				Scotland:			Northern Ireland:						
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function		HSC REC	HSC Data Guardians	Prisons	National coordinating function
Change 1:	Y	Y				(Y)				(Y)				(Y)				(Y)	A
Change 2:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 3:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 4:	Y	N				Y				Y				Y				Y	C
Change 5:	N	N				(Y)				(Y)				(Y)				(Y)	A
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	
Overall amendment type:	Substantial for review																		
Overall Category:	A																		